# Alain Munoz

> Alain Munoz is a post-ipo equity investor at Idinvest Partners backing Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Idinvest Partners](https://shizune.co/investors/profile/idinvest-partners)
- Location: Dijon, France
- Total investments: 2
- Last investment: Mar 2024
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/munoz-alain/8/825/a97

Alain Munoz is a Chairman of the Board at Acticor Biotech.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Pharmaceutical | 2 | 100% |
| Biopharma | 1 | 50% |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 50% |
| United States | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Acticor Biotech | Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $8.7M | Post-IPO Equity | Mar 15, 2024 |  |
| Santen Pharmaceutical | Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions. | $16.5M | Post-IPO Equity | Sep 26, 2009 |  |

2 of 2 investments shown.

## Co-investors
- [Auriga Partners](https://shizune.co/investors/profile/auriga-partners) — VC Fund, 1 deal together
- [Innovation Capital](https://shizune.co/investors/profile/cdc-innovation) — VC Fund, 1 deal together
- [Mediolanum Farmaceutici S.p.A.](https://shizune.co/investors/profile/mediolanum-farmaceutici-s-p-a) — VC Fund, 1 deal together
- [UI Investissement](https://shizune.co/investors/profile/ui-gestion) — VC Fund, 1 deal together

## About Idinvest Partners

VC Fund · Paris, France

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

5 contacts available at Idinvest Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Alain Munoz | Venture Partner | https://shizune.co/investors/profile/alain-munoz |
| Alban Wyniecki | Managing Director | https://shizune.co/investors/profile/alban-wyniecki |
| Benoist Grossmann | Managing Director | https://shizune.co/investors/profile/benoist-grossmann |
| Chloe Giard | Investment Director | https://shizune.co/investors/profile/chloe-giard |
| Louis Bô | Investment Director | https://shizune.co/investors/profile/b%C3%B4-louis |

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Alain Munoz invest in?

Alain Munoz invests primarily in Biotechnology, Pharmaceutical and Biopharma startups, most often at Post-IPO Equity stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alain Munoz last invest?

The most recent investment recorded for Alain Munoz closed in Mar 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co